drugset
drugset / Trial / NCT03968159

Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

NCT03968159 ↗

Phase 3 Completed 298 enrolled ACADIA Pharmaceuticals Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy and safety of adjunctive pimavanserin compared to placebo in subjects with major depressive disorder who have an inadequate response to antidepressant therapy

Timeline

Start
2019-04-25
Primary completion
2020-04-30
Completion
2020-05-29

Outcome

Missed primary endpoint

registry analysis (superiority test); Pimavanserin vs Placebo; p = 0.2956; LSM difference -0.9 (95% CI -2.5 to 0.8); NCT03968159 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimavanserin Small molecule 34 mg Oral

Indications

No indication recorded.